Neurontin...                                                    


Pfizer, Inc., Parke-Davis and Warner Lambert concocted uses for the drug NEURONTIN® (gabapentin) and promoted off-label uses for which the drug had no effect, and for which there is no scientific basis to prescribe the drug. This drug was originally sold by Parke-Davis, which was a subsidiary of Warner Lambert, which in turn was acquired by Pfizer, Inc. in 2000-2001. Through its sales of NEURONTIN®, these companies made profits which exceeded 3 billion dollars. The manufacturer of NEURONTIN® fraudulently marketed this drug to doctors as a treatment for the following illnesses:

  • Bipolar Disorder
  • Pain Syndromes, Peripheral Neuropathy, Diabetic Neuropathy
  • Reflex Sympathetic Dystrophy (RSD)
  • Attention Deficit Disorder (ADD)
  • Restless Leg Syndrome (RLS)
  • Trigeminal Neuralgia
  • Essential Tremor Periodic Limb Movement
  • Migraines
  • Drug and Alcohol Withdrawal Seizures
If you were prescribed NEURONTIN® as a treatment for any of the above illnesses, you may be entitled to reimbursement for the costs of this medicine and other damages. It has been alleged that NEURONTIN® has caused numerous adverse health conditions including suicide/attempted suicide and/or suicidal thoughts, memory loss, liver failure, kidney failure, heart attack, strokes and high blood pressure. If you are interested in potentially receiving reimbursement for the money you spent filling prescriptions for NEURONTIN® and/or your personal injury claim, you should complete our claim form.

News...
 

Unfortunately, there are no new updates in the Neurontin litigation at this time. The case has been stuck in pre-trial discovery for almost 2 years. Discovery is where the Plaintiffs (us) and the defendants exchange information and documents to prepare for trial. We have had many battles with Pfizer releasing many documents we deem necessary for trial. We are hopeful that by the end of this year the first case will be going to trial.

We will be sure to notify you of any changes or updates in the case. In the meantime please be patient and notify us if any of your contact information changes. (2/5/07) 
 

No new updates.  (8/1/06) 

Court sends Neurontin MDL to Boston, MA.     (10/30/04)

Daniel Becnel named co-chair to the Neurontin Litigation Group by the Association of Trial   Lawyers of America (ATLA).